Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure
Discovery of the activating EGFR mutation gene has revolutionized the treatment of patients with NSCLC. Nevertheless, resistance to first-line EGFR tyrosine kinase inhibitors (TKIs) develops in most patients with EGFR-mutant NSCLC after a period of 9 to 13 months. Here, we reported a case of fi...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier Inc.
2017
|
| Subjects: | |
| Online Access: | http://ir.unimas.my/id/eprint/19173/ http://ir.unimas.my/id/eprint/19173/7/Small%20Cell.pdf |
| _version_ | 1848838653412900864 |
|---|---|
| author | Chee, Shee Chai |
| author_facet | Chee, Shee Chai |
| author_sort | Chee, Shee Chai |
| building | UNIMAS Institutional Repository |
| collection | Online Access |
| description | Discovery of the activating EGFR mutation gene has
revolutionized the treatment of patients with NSCLC.
Nevertheless, resistance to first-line EGFR tyrosine
kinase inhibitors (TKIs) develops in most patients with
EGFR-mutant NSCLC after a period of 9 to 13 months.
Here, we reported a case of first-line EGFR TKI failure
attributed to SCLC transformation and T790M mutation |
| first_indexed | 2025-11-15T06:58:58Z |
| format | Article |
| id | unimas-19173 |
| institution | Universiti Malaysia Sarawak |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T06:58:58Z |
| publishDate | 2017 |
| publisher | Elsevier Inc. |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | unimas-191732022-06-08T07:56:39Z http://ir.unimas.my/id/eprint/19173/ Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure Chee, Shee Chai R Medicine (General) Discovery of the activating EGFR mutation gene has revolutionized the treatment of patients with NSCLC. Nevertheless, resistance to first-line EGFR tyrosine kinase inhibitors (TKIs) develops in most patients with EGFR-mutant NSCLC after a period of 9 to 13 months. Here, we reported a case of first-line EGFR TKI failure attributed to SCLC transformation and T790M mutation Elsevier Inc. 2017 Article PeerReviewed text en http://ir.unimas.my/id/eprint/19173/7/Small%20Cell.pdf Chee, Shee Chai (2017) Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure. Journal of Thoracic Oncology, 12 (10). pp. 171-173. ISSN 1556-0864 http://www.jto.org/article/S1556-0864(17)30568-3/pdf DOI: http://dx.doi.org/10.1016/j.jtho.2017.06.068 |
| spellingShingle | R Medicine (General) Chee, Shee Chai Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure |
| title | Small Cell Transformation and T790M Mutation as
Coresistance Mechanisms for First-line Epidermal
Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure |
| title_full | Small Cell Transformation and T790M Mutation as
Coresistance Mechanisms for First-line Epidermal
Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure |
| title_fullStr | Small Cell Transformation and T790M Mutation as
Coresistance Mechanisms for First-line Epidermal
Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure |
| title_full_unstemmed | Small Cell Transformation and T790M Mutation as
Coresistance Mechanisms for First-line Epidermal
Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure |
| title_short | Small Cell Transformation and T790M Mutation as
Coresistance Mechanisms for First-line Epidermal
Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure |
| title_sort | small cell transformation and t790m mutation as
coresistance mechanisms for first-line epidermal
growth factor receptor (egfr) tyrosine kinase inhibitor (tki) therapy failure |
| topic | R Medicine (General) |
| url | http://ir.unimas.my/id/eprint/19173/ http://ir.unimas.my/id/eprint/19173/ http://ir.unimas.my/id/eprint/19173/ http://ir.unimas.my/id/eprint/19173/7/Small%20Cell.pdf |